The ACR is aware of the emerging concerns surrounding access to needed treatments such as #MTX after the recent decision in Dobbs v. Jackson Women’s Health Organization. 
We are following this issue closely to determine if #rheum providers & patients are experiencing any widespread difficulty accessing #MTX
or if any initial disruptions are potentially temporary & due to the independent actions of pharmacists trying to figure out what is & isn’t allowed where they practice.
The ACR has assembled a task force of medical & policy experts to determine the best course of action for ensuring our patients keep access to treatments they need.
In the meantime, we are asking members & patients who have experienced challenges accessing #MTX to email advocacy@rheumatology.org with details.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
